WO2023287322A1 - Средство для коррекции митохондриальной дисфункции - Google Patents
Средство для коррекции митохондриальной дисфункции Download PDFInfo
- Publication number
- WO2023287322A1 WO2023287322A1 PCT/RU2022/050007 RU2022050007W WO2023287322A1 WO 2023287322 A1 WO2023287322 A1 WO 2023287322A1 RU 2022050007 W RU2022050007 W RU 2022050007W WO 2023287322 A1 WO2023287322 A1 WO 2023287322A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- mitochondrial
- animals
- cells
- drug
- Prior art date
Links
- 230000004065 mitochondrial dysfunction Effects 0.000 title abstract description 12
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 17
- 230000001419 dependent effect Effects 0.000 claims abstract description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000004060 metabolic process Effects 0.000 claims abstract description 9
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 3
- 238000010255 intramuscular injection Methods 0.000 claims abstract description 3
- 239000007927 intramuscular injection Substances 0.000 claims abstract description 3
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 230000002438 mitochondrial effect Effects 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 33
- 239000003814 drug Substances 0.000 abstract description 22
- 210000001700 mitochondrial membrane Anatomy 0.000 abstract description 9
- 238000012937 correction Methods 0.000 abstract description 7
- 239000011780 sodium chloride Substances 0.000 abstract description 7
- 238000010171 animal model Methods 0.000 abstract description 5
- 239000000644 isotonic solution Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 229940079593 drug Drugs 0.000 description 20
- 210000003470 mitochondria Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 239000000178 monomer Substances 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 235000019643 salty taste Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 230000027829 mitochondrial depolarization Effects 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000699696 Meriones Species 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 108010017307 cerebrocurin Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- ZGFPIGGZMWGPPW-UHFFFAOYSA-N formaldehyde;formic acid Chemical compound O=C.OC=O ZGFPIGGZMWGPPW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000012241 membrane hyperpolarization Effects 0.000 description 1
- 230000010291 membrane polarization Effects 0.000 description 1
- 238000003266 membrane potential measurement method Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A61K31/115—Formaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- the invention relates to the field of experimental medicine and concerns the creation of a new effective agent for correcting mitochondrial dysfunction in laboratory animals.
- Mitochondrial diseases include disorders caused by a wide variety of molecular damage or defects, the phenotypic manifestation of the disease being further complicated by the stochastic distributions of mitochondria in different tissues.
- a genetic construct for the correction of mitochondrial dysfunction is known (see RF patent D 1 "2642972 according to IPC class A61K48 / Q0, published on January 29, 2018), which is a section of mitochondrial DNA that is absent in mutant DNA, containing nucleotide sequences complementary to oligonucleotides at the ends SEQ ID N°1 and SEQ ID N°2 from the set of oligonucleotides.
- this drug showed the best results when administered intracerebral (injection directly into the brain) in a study on Mongolian gerbils (Meriones uniculatus). This method of administration is traumatic and undesirable for mass use of the drug.
- an immunomodulatory agent for injection containing the active ingredient and targeted additives (see RF patent N ° 2077882 according to class IPC A61K 31/115, pub. 27.04.1997).
- active principle it contains formaldehyde, and as target additives NaCl and distilled water, while it is an injection solution containing, wt.%: formaldehyde 0.07 0.24, NaCl 0.9 0.95, distilled water - the rest is up to 100%.
- the technical problem of the claimed invention is the creation of an effective and easy-to-use agent for the correction of mitochondrial dysfunction in the experiment.
- the technical result is an increase in the membrane potential of mitochondria and an increase in the oxygen-dependent metabolism of neutrophils.
- the technical result is achieved by using an immunomodulating agent for intramuscular injections containing formic aldehyde in an amount of 0.076-0.078% in an isotonic sodium chloride solution of 0.85-0.95% concentration as a means to increase the membrane potential of mitochondria and increase the oxygen-dependent metabolism of neutrophils.
- Fig. 1 subpopulations of blood cells of mice of all groups, assessed for the inclusion of mitochondrial dye JC-1 and apoptosis marker BCL-2, where A is an assessment of the dy potential of mitochondria within lymphocytes (CD45+ Ly6G-), monocytes (Ly6G+Cd45+) and neutrophils ( Ly6G+CD451ow), B - the amount of BCL-2+, the main protein involved in cell apoptosis. in fig.
- 2 is an example of assessing the dy potential of mitochondria of various populations, as well as the proportions of monomers and aggregates of mouse lymphocytes, neutrophils and monocytes: within monocytes (population of Ly6G+Cd45+ cells), within neutrophils (population of Ly6G+CD451ow cells), B - proportion of monomers (lower right quadrant) - 68.5% and proportion of aggregates (activated cells, upper right quadrant) - 30, 8% within the lymphocyte population; B - the proportion of monomers (lower right quadrant) - 92.7% and the proportion of aggregates (upper right quadrant) - 7.3% within neutrophils; D - the proportion of monomers (lower right quadrant) - 66.1% and the proportion of aggregates (activated cells, upper right quadrant) - 33.9% within the population of monocytes.
- aqueous solution of formic aldehyde (formaldehyde formic acid) is a clear, colorless liquid with a peculiar pungent odor, miscible with water and alcohol in all proportions.
- Formic aldehyde is a representative of the class of HCO aldehydes. It is a colorless gas with a pungent odor. weight 30.03, its density at 20°C is 0.815, melting point 92°C, boiling point 19.2°C. Let's well dissolve in water, alcohol.
- Isotonic sodium chloride solution for injection is a colorless transparent liquid with a salty taste.
- the solution is sterile, non-pyrogenic.
- the claimed product is a clear, colorless, odorless liquid with a slightly salty taste.
- the tool is prepared as follows.
- mice 140 mature F1 hybrid male mice (CBAxC57B16). Animals were kept in standard polypropylene boxes for keeping animals under vivarium conditions, under natural light conditions, on a standard diet (piled feed PK-120-1000
- the agent was administered once intramuscularly at a dose of 12.5 ml/kg, which corresponded to 0.25 ml of the drug per mouse (the average body weight of mice was 20.5 ⁇ 0.24 g). Animals were slaughtered by decapitation under ether anesthesia 1, 3 and 24 hours after drug administration. Control animals were injected intramuscularly with 0.25 ml of 0.9% sodium chloride solution (physiological saline).
- mitochondrial depolarization is one of the first events that occurs during apoptosis and may even be a prerequisite for the release of cytochrome c.
- the depolarization of the dy indicator may indirectly indicate a decrease in the functional potential of the mitochondrial membrane, i.e., their deactivation, possibly eventually leading to cell death.
- the fluorescence emission spectrum of JC-1 depends on its concentration, which, in turn, is determined by the dy state.
- JC-1 can exist in two different states, aggregates or monomers, each with different emission spectra.
- JC-1 forms monomers at low dye concentrations and aggregates at higher concentrations.
- Both JC-1 aggregates and monomers exhibit fluorescence in the green end of the spectrum, which is measured in the green channel (FL-1) on flow cytometers.
- JC-1 When living cells are incubated with JC-1, JC-1 enters the plasma membrane of the cell as a monomer. The absorption of JC-1 into mitochondria is due to dy. Further, Dy of normal, healthy mitochondria is polarized and JC-1 is quickly absorbed by such mitochondria. This uptake increases the concentration gradient of JC-1, resulting in the formation of JC-1 aggregates (known as J-aggregates) in mitochondria.
- JC-1 aggregates exhibit a red spectral shift resulting in higher levels of red fluorescence emission, which is measured in the red channel (FL-2) on most flow cytometers.
- JC-1 dye can be used as both a qualitative (taking into account the shift from green to red fluorescence emission) and a quantitative (taking into account only the pure fluorescence intensity) measure of the mitochondrial membrane potential.
- Accumulation of fluorescent dyes in mitochondria can be optically detected using flow cytometry, fluorescence microscopy, confocal microscopy, and using a fluorescent plate reader.
- fluorescence coefficient determination gives researchers the ability to compare membrane potential measurements as well as estimate the percentage of mitochondrial depolarization occurring in a pathological state (eg, cellular stress, apoptosis, etc.).
- Mitochondrial dy potential and BCL-2+ cell counts were studied immunologically using blood flow cytometry techniques within several mouse whole blood populations.
- leukocytes - CD45+ cells within lymphocytes (population of CD45+ Ly6G-), within monocytes (population of Ly6G+Cd45+ cells), within neutrophils (population of Ly6G+CD451ow cells), and additionally the number of BCL-2+ cells was estimated within CD45+CD3+ T cells. The estimated populations are shown in Figs. 1 A, B.
- FIG. 2A shows a scatter plot of cell locations of the sample populations being assessed within lymphocytes (CD45+ Ly6G- population), within monocytes (Ly6G+Cd45+ cell population), within neutrophils (Ly6G+CD451ow cell population).
- FIG. 2B shows that the proportion of monomers (lower right quadrant) is 68.5%.
- the proportion of aggregates (activated cells, upper right quadrant) is 30.8% within the mouse blood lymphocyte population.
- FIG. 2B shows that the proportion of monomers (lower right quadrant) is 92.7%.
- the proportion of aggregates (upper right quadrant) is 7.3% within neutrophils.
- FIG. 2 G the proportion of monomers (lower right quadrant) - 66.1%. Aggregate proportion (upper right quadrant) - 33.8% within mouse peripheral blood monocytes.
- Example 2 The evaluation of oxygen-dependent activation of neutrophils was carried out by the chemiluminescence method.
- the ring of mononuclear cells was carefully taken, the mononuclear cells were transferred into a test tube and diluted with Hanks' solution with heparin 1:5, carefully resuspended and centrifuged for 10 minutes at 3000 rpm. The supernatant was removed from the resulting sample, and the precipitate was dispersed in 2 ml of Hanks' working solution with heparin.
- the program was launched on the LKB WALLAC 1251 Luminometer and the luminol-dependent zymosan-induced chemiluminescence was evaluated in 10 cuvettes with control samples and in 10 cuvettes with experimental samples with a total cell concentration in each cuvette of 1 * 10 6 in Hank's solution with the addition of luminol. Based on the number of cycles given in the program, the peak value of Imax was reached with a subsequent decrease.
- Table 1 presents the results of a study of oxygen-dependent activation of neutrophils by chemiluminescence 3 hours after the administration of the agent.
- the data obtained allow us to speak about a significant increase in the oxygen-dependent metabolism of neutrophils under the influence of the test drug, which can be indirectly regarded as the activation of mitochondria in this cell subpopulation (see Fig. 4).
- the horizontal axis shows the numbers of the studied cuvettes, and the vertical axis shows the values of the index Imax, mV.
- FIG. 6 shows a comparison of the average values of chemiluminescence in all analyzed groups.
- the horizontal axis indicates the time of the study after the injection of the drug, and the vertical axis indicates the results of Imax, mV.
- the figure 6 shows a comparison of the average indicators of chemiluminescence in all analyzed groups and it is clear that under the influence of the proposed agent, oxygen-dependent activation of neutrophils is manifested. At the same time, the maximum effect was detected a day after the administration of the drug, this effect persisted for three weeks, gradually decreasing.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280045462.8A CN117715631A (zh) | 2021-07-12 | 2022-01-13 | 治疗线粒体功能障碍的药物 |
EP22842551.8A EP4371561A1 (en) | 2021-07-12 | 2022-01-13 | Agent for correcting mitochondrial dysfunction |
ZA2024/00909A ZA202400909B (en) | 2021-07-12 | 2024-01-26 | Drug for correction of mitochondrial dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021120402 | 2021-07-12 | ||
RU2021120402A RU2765467C1 (ru) | 2021-07-12 | 2021-07-12 | Средство для коррекции митохондриальной дисфункции |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023287322A1 true WO2023287322A1 (ru) | 2023-01-19 |
Family
ID=80214608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2022/050007 WO2023287322A1 (ru) | 2021-07-12 | 2022-01-13 | Средство для коррекции митохондриальной дисфункции |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4371561A1 (ru) |
CN (1) | CN117715631A (ru) |
RU (1) | RU2765467C1 (ru) |
WO (1) | WO2023287322A1 (ru) |
ZA (1) | ZA202400909B (ru) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2077882C1 (ru) | 1995-11-21 | 1997-04-27 | Владислав Николаевич Ласкавый | Иммуномодулирующее средство |
RU2146134C1 (ru) | 1999-06-29 | 2000-03-10 | Ласкавый Владислав Николаевич | Антивирусный препарат для инъекций |
RU2352331C1 (ru) | 2007-07-04 | 2009-04-20 | Владислав Николаевич Ласкавый | Средство, обладающее холестеринорегулирующим действием |
RU2376985C1 (ru) | 2008-07-17 | 2009-12-27 | Владислав Николаевич Ласкавый | Средство для активации стволовых клеток |
UA104516C2 (ru) | 2012-10-04 | 2014-02-10 | Анатолій Климентійович Завойський | Люлька для отделочных работ на фасадах домов |
US20140065099A1 (en) * | 2011-02-15 | 2014-03-06 | Ecole Polytechnique Federale De Lausanne (Epfl) | Methods of Treating Mitochondrial Dysfunction |
RU2642972C1 (ru) | 2016-12-26 | 2018-01-29 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ коррекции митохондриальной дисфункции с помощью генетической конструкции |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2738719C1 (ru) * | 2020-03-26 | 2020-12-15 | Владислав Николаевич Ласкавый | Средство для лечения коронавирусных, ретровирусных инфекций и гепатита с |
-
2021
- 2021-07-12 RU RU2021120402A patent/RU2765467C1/ru active
-
2022
- 2022-01-13 EP EP22842551.8A patent/EP4371561A1/en active Pending
- 2022-01-13 CN CN202280045462.8A patent/CN117715631A/zh active Pending
- 2022-01-13 WO PCT/RU2022/050007 patent/WO2023287322A1/ru active Application Filing
-
2024
- 2024-01-26 ZA ZA2024/00909A patent/ZA202400909B/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2077882C1 (ru) | 1995-11-21 | 1997-04-27 | Владислав Николаевич Ласкавый | Иммуномодулирующее средство |
RU2146134C1 (ru) | 1999-06-29 | 2000-03-10 | Ласкавый Владислав Николаевич | Антивирусный препарат для инъекций |
RU2352331C1 (ru) | 2007-07-04 | 2009-04-20 | Владислав Николаевич Ласкавый | Средство, обладающее холестеринорегулирующим действием |
RU2376985C1 (ru) | 2008-07-17 | 2009-12-27 | Владислав Николаевич Ласкавый | Средство для активации стволовых клеток |
US20140065099A1 (en) * | 2011-02-15 | 2014-03-06 | Ecole Polytechnique Federale De Lausanne (Epfl) | Methods of Treating Mitochondrial Dysfunction |
UA104516C2 (ru) | 2012-10-04 | 2014-02-10 | Анатолій Климентійович Завойський | Люлька для отделочных работ на фасадах домов |
RU2642972C1 (ru) | 2016-12-26 | 2018-01-29 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ коррекции митохондриальной дисфункции с помощью генетической конструкции |
Non-Patent Citations (1)
Title |
---|
ANONYMOUS: "Mitochondrial Diseases ", CLEVELAND CLINIC, 31 May 2018 (2018-05-31), XP093025536, Retrieved from the Internet <URL:https://my.clevelandclinic.org/health/diseases/15612-mitochondrial-diseases> [retrieved on 20230220] * |
Also Published As
Publication number | Publication date |
---|---|
EP4371561A1 (en) | 2024-05-22 |
CN117715631A (zh) | 2024-03-15 |
RU2765467C1 (ru) | 2022-01-31 |
ZA202400909B (en) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kerr et al. | Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex | |
Goossens et al. | Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. | |
Troiano et al. | Mitochondrial membrane potential and DNA stainability in human sperm cells: a flow cytometry analysis with implications for male infertility | |
CA2467333A1 (en) | Methods for monitoring amyotrophic lateral sclerosis | |
CN101968484B (zh) | 一种利用斑马鱼筛选线粒体靶向化合物的方法 | |
JP2001520990A (ja) | ポリアミンアナログを使用するマクロファージ増殖を調節するための方法 | |
Smith et al. | A comparative morphologic and physiologic study of fish blood | |
CN111358790B (zh) | Nsc228155在制备防治急性肾损伤的药物中的用途 | |
Liu et al. | Cytoskeletal alterations in human fetal astrocytes induced by interleukin‐1β | |
WO2017156362A1 (en) | Modulating t cell survival by targeting the one-carbon metabolic pathway | |
RU2765467C1 (ru) | Средство для коррекции митохондриальной дисфункции | |
EP3377095B1 (en) | Methods and pharmaceutical compositions for treating rhabdomyolysis | |
Lang et al. | Impact of ambient temperature on inflammation-induced encephalopathy in endotoxemic mice—role of phosphoinositide 3-kinase gamma | |
Harun et al. | Effects of Toxoplasma gondii infection on the function and integrity of human cerebrovascular endothelial cells and the influence of verapamil treatment in vitro | |
Chen et al. | Trpm2 deficiency in microglia attenuates neuroinflammation during epileptogenesis by upregulating autophagy via the AMPK/mTOR pathway | |
JP6281831B2 (ja) | 神経変性疾患の制御因子 | |
US10031128B2 (en) | Screening method, screening kit and analysis program | |
CN103667457B (zh) | 检测白血病BCR/ABL b3a2,b2a2融合基因相对表达量的引物和方法 | |
Gao et al. | Infection with Trypanosoma lewisi or Trypanosoma musculi may promote the spread of Toxoplasma gondii | |
van Ebbenhorst Tengbergen | The morphology of the mouse anterior pituitary during the oestrous cycle | |
RU2310196C2 (ru) | Способ определения функциональной активности симпато-адреналовой системы | |
KR20230080367A (ko) | 백혈구 핵 선택적 염색을 위한 시약 및 이를 이용한 염색 방법 | |
CN118150536A (zh) | 脊髓背角线粒体膜电位检测方法 | |
ATHANASOPOULOS et al. | Studies on the use of new methods in view of the early diagnosis of fish diseases. | |
Cossarizza et al. | Mitochondria Functionality During HIV Infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22842551 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202393401 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280045462.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022842551 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022842551 Country of ref document: EP Effective date: 20240212 |